Consistent with several recent publications regarding the synergistic anti-tumor activity of rapamycin and sorafenib [5], [26], [27], our findings further demonstrate a novel mechanism that sorafenib enhances the anti-tumor effect of rapamycin through blockade of this PDGFRβ-dependent feedback loop. Here, PDGFRB is linked to neoplasm.